Izokibep, a Unique IL-17A Inhibitor, Improves Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis up to Week 46 Phase 2 RCT Results

被引：0
|
作者：
Taylor, Peter C. [1 ]
de Vlam, Kurt [2 ]
Mease, Philip J. [3 ,4 ]
Peloso, Paul M. [5 ]
Wetzel, Dieter [6 ]
Lertratanakul, Apinya [7 ]
Brun, Nikolai [8 ]
Wiens, Brian [9 ]
Brandt-Juergens, Jan
Drescher, Edit [10 ]
Dokoupilova, Eva [11 ,12 ]
Rowinska-Osuch, Anna [13 ]
Martin, Nadia Abdel-Kader [14 ]
Behrens, Frank [15 ,16 ]
机构：
[1] Univ Oxford, Nuffield Dept Orthoped Rheumatol & Musculoskeleta, Oxford, England
[2] Univ Hosp Leuven, Leuven, Belgium
[3] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA
[4] Univ Washington, Sch Med, Seattle, WA USA
[5] ACELYRIN INC, Naples, FL USA
[6] Toclinco GmbH, Freiburg, Germany
[7] ACELYRIN, Chicago, IL USA
[8] Affibody AB, Solna, Sweden
[9] ACELYRIN Inc, Half Moon Bay, CA USA
[10] Csolnoky Ferenc Hosp, Vital Med Ctr Private Clin, Veszprem, Hungary
[11] Masaryk Univ, Fac Pharm, Dept Pharmaceut Technol, Brno, Czech Republic
[12] MED PLUS Sro, Brno, Czech Republic
[13] ETG Warszawa, Warsaw, Poland
[14] Hosp Quironsalud Infanta Luisa, Seville, Spain
[15] Goethe Univ, Div Rheumatol, Univ Hosp, Frankfurt, Germany
[16] Fraunhofer Inst Translat Med & Pharmacol, Frankfurt, Germany
来源：
ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1431
引用
收藏
页码：2814 / 2816
页数：3
相关论文
共 50 条
  • [41] Relationships Between Psoriatic Arthritis Disease Activity Score and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
    Coates, Laura
    Bushmakin, Andrew
    FitzGerald, Oliver
    Gladman, Dafna
    Fallon, Lara
    Cappelleri, Joseph
    Hsu, Ming-Ann
    Helliwell, Philip
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [42] Efficacy of Secukinumab on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Post Hoc Analysis from a Phase 3 Trial
    Strand, Vibeke
    Kaeley, Gurjit
    Bergman, Martin
    Gladman, Dafna
    Coates, Laura
    Hur, Peter
    Kim, Nina
    Parikh, Bhumik
    Pertel, Patricia
    Mease, Philip
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [43] THE IMPACT OF ADALIMUMAB VS PLACEBO ON PATIENT-REPORTED OUTCOMES AND UTILITY MEASURES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE PSORIATIC ARTHRITIS
    Strand, V.
    Patel, P.
    Chen, N.
    Lesser, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1718 - 1719
  • [44] The Impact of Adalimumab vs Placebo on Patient-Reported Outcomes and Utility Measures Among Patients with Moderately to Severely Active Psoriatic Arthritis
    Strand, Vibeke
    Patel, Pankaj
    Chen, Naijun
    Lesser, Elizabeth M.
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [45] The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2
    Kristensen, L. E.
    Soliman, A. M.
    Papp, K.
    Barcomb, L.
    Eldred, A.
    Ostor, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (11) : 2120 - 2129
  • [46] SECUKINUMAB IMPROVES CLINICAL AND PATIENT-REPORTED OUTCOMES AT 6 MONTHS AMONG PATIENTS WITH PSORIATIC ARTHRITIS IN THE US-BASED CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS (PSA/SPA) REGISTRY
    Mease, P. J.
    Blachley, T.
    Glynn, M.
    Dube, B.
    Mclean, R.
    Kim, N.
    Hur, P.
    Ogdie, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1165 - 1165
  • [47] Canakinumab Improves Patient-Reported Outcomes in Patients with Recurrent Fever Syndromes: Results from a Phase 3 Trial
    Lachmann, Helen
    Lauwerys, Bernard
    Miettunen, Paivi
    Kallinich, Tilmann
    Jansson, Annette
    Rosner, Itzhak
    Manna, Raffaele
    Murias, Saramaria
    Savic, Sinisa
    Smeets, Serge
    De Benedetti, Fabrizio
    Simon, Anna
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [48] Effects of Intravenous Golimumab on Patient-Reported Outcomes in Active Ankylosing Spondylitis: 28-Week Results of the Phase 3 Trial
    Reveille, John D.
    Deodhar, Atul A.
    Chan, Eric K. H.
    Peterson, Steven
    Li, Nan
    Hsia, Elizabeth C.
    Kim, Lilianne
    Lo, Kim Hung
    Harrison, Diane D.
    Han, Chenglong
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [49] USTEKINUNLth AND CUSELKUMAB TREATMENT RESULTS IN DIFFERENCES IN SERUM IL-17A, IL-17F AND CRP LEVELS IN PSORIATIC ARTHRITIS PATIENTS: A COMPARISON FROM USTEKINUMAB PHASE 3 AND GUSELKUMAB PHASE 2 PROGRAMS
    Siebert, Stefan
    Loza, Matthew J.
    Song, Qingxuan
    McInnes, Lain B.
    Zazzetti, Federico
    Sweet, Kristen
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 25 - 25
  • [50] Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial
    Behrens, Frank
    Taylor, Peter
    Mease, Philip J.
    Peloso, Paul
    Wetzel, Dieter
    Brun, Nicolai
    Wiens, Brian
    Brandt-Juergens, Jan
    Drescher, Edit
    Dokoupilova, Eva
    Rowinska-Osuch, Anna
    Abdel-Kader Martin, Nadia
    de Vlam, Kurt
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3164 - 3166
12345